- Home
- FPAY vs SBFM Comparison
FPAY vs SBFM Comparison
Compare FPAY & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPAY
- SBFM
- Stock Information
- Founded
- FPAY 2003
- SBFM 2006
- Country
- FPAY United States
- SBFM United States
- Employees
- FPAY N/A
- SBFM N/A
- Industry
- FPAY Diversified Commercial Services
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- FPAY Consumer Discretionary
- SBFM Health Care
- Exchange
- FPAY Nasdaq
- SBFM Nasdaq
- Market Cap
- FPAY N/A
- SBFM 4.9M
- IPO Year
- FPAY N/A
- SBFM N/A
- Fundamental
- Price
- FPAY $1.14
- SBFM $1.28
- Analyst Decision
- FPAY Strong Buy
- SBFM Strong Buy
- Analyst Count
- FPAY 2
- SBFM 1
- Target Price
- FPAY $3.25
- SBFM $15.00
- AVG Volume (30 Days)
- FPAY 55.7K
- SBFM 4.2M
- Earning Date
- FPAY 05-12-2025
- SBFM 05-19-2025
- Dividend Yield
- FPAY N/A
- SBFM N/A
- EPS Growth
- FPAY N/A
- SBFM N/A
- EPS
- FPAY N/A
- SBFM N/A
- Revenue
- FPAY $134,563,007.00
- SBFM $34,874,283.00
- Revenue This Year
- FPAY $25.78
- SBFM $192.48
- Revenue Next Year
- FPAY $6.46
- SBFM N/A
- P/E Ratio
- FPAY N/A
- SBFM N/A
- Revenue Growth
- FPAY 24.46
- SBFM 44.75
- 52 Week Low
- FPAY $0.97
- SBFM $1.17
- 52 Week High
- FPAY $2.37
- SBFM $33.60
- Technical
- Relative Strength Index (RSI)
- FPAY 39.29
- SBFM 36.43
- Support Level
- FPAY $0.99
- SBFM $1.17
- Resistance Level
- FPAY $1.44
- SBFM $1.65
- Average True Range (ATR)
- FPAY 0.09
- SBFM 0.31
- MACD
- FPAY 0.01
- SBFM -0.02
- Stochastic Oscillator
- FPAY 47.47
- SBFM 8.46
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.